Fortis Diagnostics unit gets new CEO as Vijender Singh takes over Agilus
Former Metropolis chief brings 30+ years of experience to lead Agilus's **410+ labs** and **3,700+ touchpoints**.
— 8 earlier stories on Fortis Healthcare Ltd. →What's new
- Fortis appoints Vijender Singh as MD & CEO of diagnostics arm Agilus.
- Anand K steps down after nearly six years.
- Singh brings experience from Metropolis, Dr. Lal PathLabs, and Healthians.
Why this matters
This is a leadership change at a subsidiary, not a parent-level shake-up. Agilus contributes significantly to Fortis's revenue, so the appointment is strategically relevant. The new CEO's track record in scaling diagnostic businesses could strengthen Agilus's market position, but the impact will unfold gradually.
What we're watching
- How Singh's strategy for Agilus evolves in the coming quarters.
- Any incremental growth in Agilus's lab network or revenue share.
- Competitive dynamics in diagnostics versus peers like Dr. Lal PathLabs and Metropolis.
The full read
Fortis Healthcare named Vijender Singh CEO of its diagnostics subsidiary Agilus, replacing Anand K after nearly six years. Singh has led Metropolis Healthcare and held senior roles at Dr. Lal PathLabs and Healthians. Hardly a shock for a ₹72,083 cr parent. But Agilus runs 410+ labs and 3,700+ touchpoints, and its contribution to consolidated revenue is meaningful. The real test is whether Singh can scale that network in a diagnostics market where rivals are already entrenched. That question won't be answered in a quarter.
Questions answered
- What is Vijender Singh's background?
- Singh has over 30 years in diagnostics, healthcare, and consumer sectors. He previously led Metropolis Healthcare and held senior roles at Dr. Lal PathLabs and Healthians.
- Why did Anand K leave?
- He resigned to pursue opportunities elsewhere. The departure appears orderly, limiting disruption risk.
- How big is Agilus Diagnostics?
- Agilus operates 410+ labs and 3,700+ customer touchpoints across India, making it a significant contributor to Fortis' consolidated revenue.
- When does Singh's term start?
- The appointment takes effect immediately.
- Is this material for Fortis stock?
- Analysts view it as a moderate importance event — relevant but not a surprise that forces a re-rating of Fortis's stock at the parent level.
Fortis Healthcare Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on FORTIS →- 20 Jul 2026 · 3:19 PM IST Fortis Diagnostics unit gets new CEO as Vijender Singh takes over Agilus
- 25d ago Fortis Healthcare enters Odisha with asset-light hospital deal
- 67d ago Fortis Healthcare reports 31.5% profit growth for FY26
- 67d ago Fortis Healthcare profits climb 31% on double-digit revenue growth
- 67d ago Fortis Healthcare confirms final dividend of ₹1 per share